Merida Biosciences has officially launched with a $121 million Series A funding round aimed at developing treatments for autoimmune and allergic diseases, beginning with Graves' disease and food allergies. The funding round includes participation from notable investors such as TRV, Bain Capital, BVF Partners, Google Ventures, and Perceptive Advisors. The biotech sector, represented by the SPDR S&P Biotech ETF ($XBI), is currently experiencing a recovery phase, although some analysts express surprise at the ETF's modest performance in light of this new funding announcement. The Series A funding is part of a broader trend of substantial investments in precision immunology, a field gaining traction among investors.